Aufgaben in der Neurologischen Klinik

Direktor
Universitätsprofessor

Klinische Qualifikationen

Facharzt für Neurologie
Zusatzbezeichnung Geriatrie
Zusatzbezeichnung Intensivmedizinarzt

Wissenschaftliche Schwerpunkte

Parkinson-Krankheit
Progressive Supranukleäre Blickparese
Corticobasale Degeneration
Multiple Systematrophie
Neurobiologie Neurodegenerativer Krankheiten
Klinische Therapiestudien

Auswahl:

• Pagano G, …, PASADENA Investigators (incl. Höglinger G); Prasinezumab Study Group. Trial of Prasinezumab in Early-Stage Parkinson's Disease. N Engl J Med. 2022;387(5):421-432.
• Franzmeier N, Brendel M, … Höglinger G#, Ewers M# (# equal contribution). Tau spreading is driven by neuronal connectivity in primary tauopathies - evidence from tau-PET and histopathology. Nature Communications, 2022;13:1362
• Lukic MJ, …, Höglinger G. Long-Duration Progressive Supranuclear Palsy: Clinical Course and Pathological Underpinnings. Annals of Neurology 2022;92(4):637-649.
• Dam T, …, Höglinger GU, …, Budd Haeberlein S; on behalf of the PASSPORT Study Group. Safety and efficacy of the monoclonal anti-tau antibody gosuranemab in progressive supranuclear palsy: the PASSPORT trial. Nature Medicine, 2021 Aug;27(8):1451-1457.
• Stamelou M, …, Höglinger GU. Evolving concepts for Progressive Supranuclear Palsy and other 4R-tauopathies. Nature Reviews Neurology 2021;17(10):601-620.
• Höglinger G, …, Florian H, on behalf of the ARISE Investigators* Evaluation of tilavonemab (ABBV-8E12) in progressive supranuclear palsy: results from a phase 2, randomised, placebo-controlled, multicentre study. Lancet Neurology 2021;20(3):182-192.
• Truong DJ, …, Höglinger GU, … Westmeyer GG. Non-invasive and high-throughput interrogation of exon-specific isoform expression. Nature Cell Biology 2021;23(6):652-663.
• Jabbari E, … Höglinger GU, … Morris HR; PSP Genetics Group. Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurology 2021;20(2):107-116.
• Kovacs GG, … Höglinger GU, Distribution patterns and sequential stages of tau pathology in progressive supranuclear palsy. Acta Neuropathology 2020;140(2):99-119.
• Hopfner F*, Höglinger GU*, Kuhlenbäumer G, Pottegård A, Wod M, Christensen K, Tanner CM, Deuschl G. β-adrenoreceptors and the risk of Parkinson's disease. Lancet Neurology 2020;19(3):247-254.
• Levin J, …, Höglinger GU. Efficacy and safety of epigallocatechin gallate for multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled phase III trial. Lancet Neurology 2019;18:724-735.
• Höglinger GU, …, Schellenberg JD. Identification of common variants influencing risk of the tauopathy Progressive Supranuclear Palsy. Nature Genetics 2011;43:699-705.